The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

GW Pharmaceuticals PLC

Nasdaq: GWPH
Last

(U.S.) $120.01

Today's change0.00 0.00%
Updated January 20 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

GW Pharmaceuticals PLC

Nasdaq: GWPH
Last

(U.S.) $120.01

Today's change0.00 0.00%
Updated January 20 4:00 PM -5GMT. Delayed by at least 15 minutes.

GW Pharmaceuticals PLC closed at (U.S.)$120.01.

Over the last five days, shares are unchanged, but have gained 109.22% over the last 52 weeks. This security has outperformed the S&P 500 by 87.07% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $120.01
  • High--
  • Low--
  • Bid / Ask(U.S.) $110.16 / (U.S.) $120.00
  • YTD % change+7.39%
  • Volume0
  • Average volume (10-day)409,650
  • Average volume (1-month)358,060
  • Average volume (3-month)544,901
  • 52-week range(U.S.) $35.83 to (U.S.) $137.88
  • Beta2.76
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEG0.47×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$3.49
Updated January 20 4:00 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-617.13%

Although this company's net profit margin is negative, it is above the industry average and implies that GW Pharmaceuticals PLC is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.00%Sector:Industry:

Latest Company News

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue2234
Total other revenue--------
Total revenue2234
Gross profit1223
Total cost of revenue1111
Total operating expense26212525
Selling / general / administrative7634
Research & development24262624
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-25-18-22-21
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax-24-18-22-21
Income after tax-17-12-17-18
Income tax, total-8-6-5-3
Net income-17-12-17-18
Total adjustments to net income--------
Net income before extra. items-17-12-17-18
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-17-12-17-18
Inc. avail. to common incl. extra. items-17-12-17-18
Diluted net income-17-12-17-18
Dilution adjustment--------
Diluted weighted average shares295263263261
Diluted EPS excluding extraordinary itemsvalue per share-0.06-0.05-0.06-0.07
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.06-0.05-0.06-0.07